Literature DB >> 22529314

Rates of hospitalizations for respiratory syncytial virus, human metapneumovirus, and influenza virus in older adults.

Kyle Widmer1, Yuwei Zhu, John V Williams, Marie R Griffin, Kathryn M Edwards, H Keipp Talbot.   

Abstract

BACKGROUND: We performed a prospective study to determine the disease burden of respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) in older adults in comparison with influenza virus.
METHODS: During 3 consecutive winters, we enrolled Davidson County (Nashville, TN) residents aged ≥ 50 years admitted to 1 of 4 hospitals with acute respiratory illness (ARI). Nasal/throat swabs were tested for influenza, RSV, and HMPV with reverse-transcriptase polymerase chain reaction. Hospitalization rates were calculated.
RESULTS: Of 1042 eligible patients, 508 consented to testing. Respiratory syncytial virus was detected in 31 participants (6.1%); HMPV was detected in 23 (4.5%) patients; and influenza was detected in 33 (6.5%) patients. Of those subjects aged ≥ 65 years, 78% received influenza vaccination. Compared with patients with confirmed influenza, patients with RSV were older and more immunocompromised; patients with HMPV were older, had more cardiovascular disease, were more likely to have received the influenza vaccination, and were less likely to report fever than those with influenza. Over 3 years, average annual rates of hospitalization were 15.01, 9.82, and 11.81 per 10,000 county residents due to RSV, HMPV, and influenza, respectively.
CONCLUSIONS: In adults aged ≥ 50 years, hospitalization rates for RSV and HMPV were similar to those associated with influenza.

Entities:  

Mesh:

Year:  2012        PMID: 22529314      PMCID: PMC3415933          DOI: 10.1093/infdis/jis309

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  44 in total

1.  Evaluation of three rapid enzyme immunoassays and cell culture for detection of respiratory syncytial virus.

Authors:  J Mendoza; A Rojas; J M Navarro; C Plata; M de la Rosa
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-05       Impact factor: 3.267

2.  Real-time reverse transcriptase PCR assay for detection of human metapneumoviruses from all known genetic lineages.

Authors:  Jeroen Maertzdorf; Chiaoyin K Wang; Jennifer B Brown; Joseph D Quinto; Marla Chu; Miranda de Graaf; Bernadette G van den Hoogen; Richard Spaete; Albert D M E Osterhaus; Ron A M Fouchier
Journal:  J Clin Microbiol       Date:  2004-03       Impact factor: 5.948

3.  Virological features and clinical manifestations associated with human metapneumovirus: a new paramyxovirus responsible for acute respiratory-tract infections in all age groups.

Authors:  Guy Boivin; Yacine Abed; Gilles Pelletier; Louisette Ruel; Danielle Moisan; Stéphanie Côté; Teresa C T Peret; Dean D Erdman; Larry J Anderson
Journal:  J Infect Dis       Date:  2002-10-08       Impact factor: 5.226

4.  An epidemic of respiratory syncytial virus in elderly people: clinical and serological findings.

Authors:  G Agius; G Dindinaud; R J Biggar; R Peyre; V Vaillant; S Ranger; J Y Poupet; M F Cisse; M Castets
Journal:  J Med Virol       Date:  1990-02       Impact factor: 2.327

5.  An outbreak of respiratory syncytial virus pneumonia in a nursing home for the elderly.

Authors:  F J Sorvillo; S F Huie; M A Strassburg; A Butsumyo; W X Shandera; S L Fannin
Journal:  J Infect       Date:  1984-11       Impact factor: 6.072

6.  Evaluation of four methods for the diagnosis of respiratory syncytial virus infection in older adults.

Authors:  A R Falsey; R M McCann; W J Hall; M M Criddle
Journal:  J Am Geriatr Soc       Date:  1996-01       Impact factor: 5.562

7.  Lack of sensitivity of rapid antigen tests for the diagnosis of respiratory syncytial virus infection in adults.

Authors:  Aida E Casiano-Colón; Barbara B Hulbert; Theodor K Mayer; Edward E Walsh; Ann R Falsey
Journal:  J Clin Virol       Date:  2003-10       Impact factor: 3.168

8.  Respiratory syncytial virus and influenza A infections in the hospitalized elderly.

Authors:  A R Falsey; C K Cunningham; W H Barker; R W Kouides; J B Yuen; M Menegus; L B Weiner; C A Bonville; R F Betts
Journal:  J Infect Dis       Date:  1995-08       Impact factor: 5.226

9.  Influenza- and respiratory syncytial virus-associated morbidity and mortality in the nursing home population.

Authors:  Shelley E Ellis; Christopher S Coffey; Edward F Mitchel; Robert S Dittus; Marie R Griffin
Journal:  J Am Geriatr Soc       Date:  2003-06       Impact factor: 5.562

10.  Viral respiratory infections in the institutionalized elderly: clinical and epidemiologic findings.

Authors:  A R Falsey; J J Treanor; R F Betts; E E Walsh
Journal:  J Am Geriatr Soc       Date:  1992-02       Impact factor: 5.562

View more
  136 in total

1.  Immunization with Low Doses of Recombinant Postfusion or Prefusion Respiratory Syncytial Virus F Primes for Vaccine-Enhanced Disease in the Cotton Rat Model Independently of the Presence of a Th1-Biasing (GLA-SE) or Th2-Biasing (Alum) Adjuvant.

Authors:  Kirsten Schneider-Ohrum; Corinne Cayatte; Angie Snell Bennett; Gaurav Manohar Rajani; Patrick McTamney; Krystal Nacel; Leigh Hostetler; Lily Cheng; Kuishu Ren; Terrence O'Day; Gregory A Prince; Michael P McCarthy
Journal:  J Virol       Date:  2017-03-29       Impact factor: 5.103

2.  Novel HLA-A2-restricted human metapneumovirus epitopes reduce viral titers in mice and are recognized by human T cells.

Authors:  Andrew K Hastings; Pavlo Gilchuk; Sebastian Joyce; John V Williams
Journal:  Vaccine       Date:  2016-04-19       Impact factor: 3.641

3.  Respiratory Viral Infection Alters the Gut Microbiota by Inducing Inappetence.

Authors:  Miriam F Moffatt; Michael J Cox; John S Tregoning; Helen T Groves; Sophie L Higham
Journal:  mBio       Date:  2020-02-18       Impact factor: 7.867

Review 4.  New Approaches for Immunization and Therapy against Human Metapneumovirus.

Authors:  Sherry C Wen; John V Williams
Journal:  Clin Vaccine Immunol       Date:  2015-06-10

Review 5.  Neutralizing epitopes on the respiratory syncytial virus fusion glycoprotein.

Authors:  Jason S McLellan
Journal:  Curr Opin Virol       Date:  2015-03-26       Impact factor: 7.090

Review 6.  [Respiratory syncytial virus].

Authors:  Jürgen Seidenberg
Journal:  Internist (Berl)       Date:  2019-11       Impact factor: 0.743

7.  Viral shedding and immune responses to respiratory syncytial virus infection in older adults.

Authors:  Edward E Walsh; Derick R Peterson; Aja E Kalkanoglu; Frances Eun-Hyung Lee; Ann R Falsey
Journal:  J Infect Dis       Date:  2013-02-04       Impact factor: 5.226

8.  Identifying Gaps in Respiratory Syncytial Virus Disease Epidemiology in the United States Prior to the Introduction of Vaccines.

Authors:  Lindsay Kim; Brian Rha; Jon S Abramson; Larry J Anderson; Carrie L Byington; Grace L Chen; John DeVincenzo; Kathryn M Edwards; Janet A Englund; Ann R Falsey; Marie R Griffin; Ruth A Karron; Karen G Martin; H Cody Meissner; Flor M Munoz; Andrew T Pavia; Pedro A Piedra; William Schaffner; Eric A F Simões; Rosalyn Singleton; H Keipp Talbot; Edward E Walsh; Jane R Zucker; Susan I Gerber
Journal:  Clin Infect Dis       Date:  2017-09-15       Impact factor: 9.079

Review 9.  Human metapneumovirus.

Authors:  Jennifer E Schuster; John V Williams
Journal:  Pediatr Rev       Date:  2013-12

10.  Soluble F proteins exacerbate pulmonary histopathology after vaccination upon respiratory syncytial virus challenge but not when presented on virus-like particles.

Authors:  Youri Lee; Young-Tae Lee; Eun-Ju Ko; Ki-Hye Kim; Hye Suk Hwang; Soojin Park; Young-Man Kwon; Sang Moo Kang
Journal:  Hum Vaccin Immunother       Date:  2017-11-02       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.